Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Daniel O. Persky, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Tetiana Perekhrestenko, MD PhD, Adolfo E Diaz, MD, Troy H. Guthrie, Jr., MD, Thomas Strack, MD, Christine Burnett, Sarah Wilson, CCRA, Tara Baetz, MD FRCPC

Blood (2019) 134 (Supplement_1): 5324.

https://doi.org/10.1182/blood-2019-128604

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Deborah A. Katz, MD, Matthew S. McKinney, MD

Blood (2019) 134 (Supplement_1): 5322.

https://doi.org/10.1182/blood-2019-124890

Published: 2019

Journal Articles

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Paul A. Hamlin, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Steven I Park, MD, Christine Burnett, Kristina Dabovic, PharmD, Eric T Williams, PhD, Jack P Higgins, PhD, Daniel O. Persky, MD

Blood (2019) 134 (Supplement_1): 4098.

https://doi.org/10.1182/blood-2019-129243

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Gary Gordon, MD PhD, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Jason Tache, DO

Blood (2019) 134 (Supplement_1): 1597.

https://doi.org/10.1182/blood-2019-128503

Published: 2019

Journal Articles

Shiga-like Toxin Producing E. coli Identified in Patients with Multiple Myeloma (MM) Hospitalized Due to Acute Onset Diarrhea; First Report on the Clinical Use of the Biofire Film Array Gastrointestinal Panel

Natalia Kreiniz, Tamar Tadmor, MD, Aaron Polliack, MD, Asala Abu-Ahmad, MD, Orit Golan-Shani, PhD, Paz Alona, MD

Blood (2018) 132 (Supplement 1): 4959.

https://doi.org/10.1182/blood-2018-99-114193

Published: 2018

Journal Articles

Complement-Mediated Thrombotic Microangiopathy: A Murky Presentation of a Rare Disease Entity

Patrick Fleming, MD, Maggie Cheung, MD, David Sokol, MD

Blood (2018) 132 (Supplement 1): 5005.

https://doi.org/10.1182/blood-2018-99-119893

Published: 2018

Journal Articles

Pregnancy-Associated Atypical Hemolytic Uremic Syndrome (aHUS), Treated with Eculizumab

Eudokia M. Mandala, Associate Professor, Spyridon Gkiouzepas, MD, Efstratios Kasimatis, MD, Christos Lafaras, MD PhD, Parthenis Chalevas, MD, Konstantina Tsioni, MD PhD, Krystallia Kyrka, MD, Dominiki Oikonomidou, MD PhD, Konstantinos Dinas, Assistant Professor, Aristotelis Loufopoulos, Professor, George Efstratiadis, Professor, Garipidou Vasilia, Professor, Anastasios-Alexandros Garyfallos, Professor

Blood (2014) 124 (21): 5019.

https://doi.org/10.1182/blood.V124.21.5019.5019

Published: 2014

Journal Articles

Novel C3 Mutation Causing Atypical Hemolytic Uremic Syndrome Successfully Treated with Eculizumab

Joao Carlos Guerra, MD PhD, Claudio Galvao de Castro, MD, Paulo Vidal Campregher, MD, Tatiana Galvao, MD, Oscar Pavao Santos, MD, Bento Cardoso Santos, MD, Luiz Vicente Rizzo, MD PhD, Flavia Munhoz Ferreira, MD, Michelle P. Silveira, MD, Nelson Hamerschlak, MD PhD, Helio Korkes, MD

Blood (2014) 124 (21): 1333.

https://doi.org/10.1182/blood.V124.21.1333.1333

Published: 2014

Journal Articles

CD20-Specific Engineered Toxin Body Demonstrates Direct Cell Kill Of Multiple B-Cell Non-Hodgkin's Lymphoma Types

Sangeetha Rajagopalan, PhD, Rachel Wirth, BS, Jennifer Erdman, Brigitte Brieschke, William Null, Jensing Liu, PhD, Erin Willert, PhD, Jack Higgins, PhD

Blood (2013) 122 (21): 5152.

https://doi.org/10.1182/blood.V122.21.5152.5152

Published: 2013

Journal Articles

Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy

Benjamin C. Lee, Chad L. Mayer, Caitlin S. Leibowitz, D. J. Stearns-Kurosawa, Shinichiro Kurosawa

Blood (2013) 122 (5): 803–806.

https://doi.org/10.1182/blood-2013-03-490060

Published: 2013

Journal Articles

Flow Driven Self-Assembly of Von Willebrand Factor Strands and Cables in Synthetic Blood Vessels

Junmei Chen, PhD, Ying Zheng, PhD, Jose A. Lopez, MD

Blood (2012) 120 (21): 261.

https://doi.org/10.1182/blood.V120.21.261.261

Published: 2012

Journal Articles

The B subunits of Shiga-like toxins induce regulated VWF secretion in a phospholipase D1–dependent manner

Jing Huang, Sandra L. Haberichter, J. Evan Sadler

Blood (2012) 120 (5): 1143–1149.

https://doi.org/10.1182/blood-2012-01-408096

Published: 2012

Journal Articles

Phospholipase D1 Is Required for Regulated Secretion of VWF Induced by the B-Subunits of Shiga-Like Toxins 1 and 2

Jing Huang, PhD, MD, Fang Liu, J. Evan Sadler, MD, PhD

Blood (2010) 116 (21): 2113.

https://doi.org/10.1182/blood.V116.21.2113.2113

Published: 2010

Journal Articles

Shiga Toxin 1(Stx1) Stimulates Endothelial Cell VWF Secretion through a Ca 2+ /PKC Signaling Pathway That Does Not Require the Active Toxin Stx1A Subunit

Fang Liu, MD, PhD, Jing Huang, PhD, MD, J. Evan Sadler, MD, PhD

Blood (2008) 112 (11): 3931.

https://doi.org/10.1182/blood.V112.11.3931.3931

Published: 2008

Journal Articles

Increased Tissue Factor Bearing Microparticles in Hemolytic Uremic Syndrome.

Morayma Reyes, MD, PhD, Wayne Leslie Chandler, MD, Sandra Watkins, MD, Jody Mooney, MD, Phillip Tarr, MD

Blood (2006) 108 (11): 1006.

https://doi.org/10.1182/blood.V108.11.1006.1006

Published: 2006

Journal Articles

Hemolytic Uremic Syndrome Is an Immune Mediated Disease: Role of Anti-CD36 Antibodies.

Gail Rock, PhD, MD, William Clark, Marion Sternbach, Maria Kolajova, Peter McLaine

Blood (2005) 106 (11): 3990.

https://doi.org/10.1182/blood.V106.11.3990.3990

Published: 2005

Journal Articles

Additional Environmental and/or Genetic Factors Are Required to Trigger TTP in ADAMTS13-Deficient Mice.

David Motto, MD, PhD, Weirui Zhang, Guojing Zhu, Jonathon Homeister, MD, PhD, Han-Mou Tsai, MD, David Ginsburg, MD

Blood (2004) 104 (11): 258.

https://doi.org/10.1182/blood.V104.11.258.258

Published: 2004

Journal Articles

What genes do Shiga toxins target?

Wayne L. Chandler

Blood (2003) 102 (4): 1151.

https://doi.org/10.1182/blood-2003-06-1857

Published: 2003

Journal Articles

Molecular and functional analysis of Shiga toxin–induced response patterns in human vascular endothelial cells

Andreas Matussek, Joerg Lauber, Anna Bergau, Wiebke Hansen, Manfred Rohde, Kurt E. J. Dittmar, Matthias Gunzer, Michael Mengel, Patricia Gatzlaff, Maike Hartmann, Jan Buer, Florian Gunzer

Blood (2003) 102 (4): 1323–1332.

https://doi.org/10.1182/blood-2002-10-3301

Published: 2003

Journal Articles

Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome

D. Maroeska W. M. te Loo, Leo A. H. Monnens, Thea J. A. M. van der Velden, Mario A. Vermeer, Frank Preyers, Pierre N. M. Demacker, Lambertus P. W. J. van den Heuvel, Victor W. M. van Hinsbergh

Blood (2000) 95 (11): 3396–3402.

https://doi.org/10.1182/blood.V95.11.3396

Published: 2000

NARROW

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Shiga-like Toxin Producing E. coli Identified in Patients with Multiple Myeloma (MM) Hospitalized Due to Acute Onset Diarrhea; First Report on the Clinical Use of the Biofire Film Array Gastrointestinal Panel

Complement-Mediated Thrombotic Microangiopathy: A Murky Presentation of a Rare Disease Entity

Pregnancy-Associated Atypical Hemolytic Uremic Syndrome (aHUS), Treated with Eculizumab

Novel C3 Mutation Causing Atypical Hemolytic Uremic Syndrome Successfully Treated with Eculizumab

CD20-Specific Engineered Toxin Body Demonstrates Direct Cell Kill Of Multiple B-Cell Non-Hodgkin's Lymphoma Types

Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy

Flow Driven Self-Assembly of Von Willebrand Factor Strands and Cables in Synthetic Blood Vessels

The B subunits of Shiga-like toxins induce regulated VWF secretion in a phospholipase D1–dependent manner

Phospholipase D1 Is Required for Regulated Secretion of VWF Induced by the B-Subunits of Shiga-Like Toxins 1 and 2

Shiga Toxin 1(Stx1) Stimulates Endothelial Cell VWF Secretion through a Ca 2+ /PKC Signaling Pathway That Does Not Require the Active Toxin Stx1A Subunit

Increased Tissue Factor Bearing Microparticles in Hemolytic Uremic Syndrome.

Hemolytic Uremic Syndrome Is an Immune Mediated Disease: Role of Anti-CD36 Antibodies.

Additional Environmental and/or Genetic Factors Are Required to Trigger TTP in ADAMTS13-Deficient Mice.

What genes do Shiga toxins target?

Molecular and functional analysis of Shiga toxin–induced response patterns in human vascular endothelial cells

Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only